AUROPHARMA
Aurobindo Pharma Limited (NSE: Auropharma) Reports Highest Ever Quarterly Revenue of INR 10,263 Cr for Q2fy27
Aurobindo Pharma Limited (NSE: AUROPHARMA) announced consolidated financial results for Q2FY27 with a record revenue of INR 10,263 Cr.
Aurobindo Pharma Limited (NSE: AUROPHARMA) today announced its consolidated financial results for the quarter ended September 30, 2026. The company reported its highest ever quarterly revenue from operations of INR 10,263 Cr, marking a 24% year-on-year increase. This growth was driven by robust performance across all business segments.
US Revenue Surges
The US revenue increased by 25% year-on-year to INR 4,555 Cr, translating to USD 477 million. This growth was primarily due to successful integration, base business growth, and new product launches.
Strong Performance Across Europe
Europe revenue rose by 27% year-on-year to INR 3,161 Cr, contributing to 31% of consolidated revenue. In euro terms, revenue increased by 18% to EUR 288 million.
Growth Markets and ARV Revenue
Growth Markets revenue increased by 16% year-on-year to INR 1,026 Cr, while ARV revenue remained stable at INR 359 Cr. The company also received final approval for 12 products from the USFDA.
As a result of these strong performances, Aurobindo Pharma Limited generated free cash flows of USD 146 million during the quarter, maintaining a net cash position of USD 189 million.
For more details, the company will host an earnings call at 8:30 AM IST on November 5, 2026. To join the call, pre-register using the link: https://bit.ly/4yDZFGo.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo rises 8.7% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 10.7% and profits at 22.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Aurobindo Pharma Limited.
AUROPHARMA
Aurobindo Pharma Limited Receives Final Approval for Perampanel Tablets from USFDA
Aurobindo Pharma Limited (NSE: AUROPHARMA) receives final approval from USFDA for Perampanel Tablets, set to launch in Q3FY27.
Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce the receipt of final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. These tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Fycompa® Tablets, of Catalyst Pharmaceuticals, Inc. The product will be manufactured at Unit -IV of APL Healthcare, a wholly-owned subsidiary of the Company, and is set to launch in Q3FY27. The approved product has an estimated market size of US$ 67 million for the twelve months ending August 2026, according to IQVIA MAT.
Significance of Approval
This approval marks a significant milestone for Aurobindo Pharma as it expands its portfolio of CNS products. Perampanel Tablets are indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 4 years and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
Company’s Growth and Future Prospects
With this approval, Aurobindo Pharma now has a total of 599 ANDA approvals from USFDA. The company continues to strengthen its position in the global pharmaceutical market with its robust product portfolio spread over seven major therapeutic areas. Aurobindo Pharma’s commitment to innovation and quality is evident in its extensive list of manufacturing and packaging facilities approved by leading regulatory agencies worldwide.
Aurobindo Pharma Limited remains dedicated to its mission of delivering high-quality, affordable medications to patients globally. With the launch of Perampanel Tablets, the company is poised to further its growth and contribute to improved patient outcomes in the epilepsy treatment landscape.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo posts a 3.5% three-month gain, but softens in the last few weeks. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 0.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.17 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.
AUROPHARMA
Aurobindo Pharma Limited Receives Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Aurobindo Pharma Limited (NSE: AUROPHARMA) receives final approval from USFDA for Beclomethasone Dipropionate HFA Inhalation Aerosol.
Aurobindo Pharma Limited (NSE: AUROPHARMA) announced today that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR® Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC. This marks Aurobindo’s first metered-dose inhaler (MDI) product, signifying a significant milestone in the company’s expansion into complex respiratory therapies and strengthening its capabilities in the inhalation segment.
Manufacturing and Market Potential
The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina, owned by its wholly-owned step-down subsidiary Aurolife Pharma LLC. The US market for the approved product and newer versions of the reference product, QVAR® Redi Haler, was estimated at US$301 million for the twelve months ended July 2026, according to IQVIA.
Therapeutic Benefits
Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for the systemic corticosteroids.
Building on our leadership in Generics, we are now expanding into complex inhalation therapies to create the next wave of differentiated growth in the US market, stated Aurobindo Pharma Limited.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo rises 14.1% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.19 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.
AUROPHARMA
Aurobindo Pharma Limited Launches Generic Advair Diskus® in US Market
Aurobindo Pharma Limited (AUROPHARMA) announces the launch of generic Advair Diskus® in the US market by its subsidiary Lannett Company LLC.
Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce that Lannett Company LLC, a wholly-owned subsidiary, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder), a product of GSK plc, in the US market. This marks the first product from Aurobindo’s inhalation pipeline to be commercialized in the US, reflecting the company’s ongoing focus on expanding its portfolio of complex and differentiated inhalation products.
Advair Diskus® for Asthma and COPD
Advair Diskus® in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch is a significant milestone for Aurobindo Pharma as it continues to build its robust portfolio in the respiratory therapeutic area.
Global Pharmaceutical Leader
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. With 30+ manufacturing and packaging facilities approved by leading regulatory agencies, Aurobindo Pharma remains committed to delivering high-quality, affordable medications worldwide.
For more information, please visit www.aurobindo.com. For further inquiries, contact Investor Relations | Corporate Communications at Phone: +91 40 667 51211 | 66725000, Email: [email protected].
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo gains 15.3% over three months and trades near its 52-week highs. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.15 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.
-
AKUMS2 days agoAkums Drugs and Pharmaceuticals Limited (akums) Q2 FY27: Revenue Up 32%, Ebitda and PAT Surge
-
Information Technology Services2 days agoOrient Technologies Limited (orienttech) Q2 FY27: Strong Profitability on Higher Managed Services Contribution
-
Consumer Cyclical2 days agoTbo Tek Limited (tbotek) Q2 FY27: Revenue Up 53%, Adj. Ebitda at ₹152 Crores
-
Aluminum2 days agoMmp Industries Limited (NSE: MMP) Reports Record Quarterly and Half-yearly Revenue; Q2fy27 Revenue Grows 35% and PAT Rises 73% Yoy
-
Basic Materials2 days agoJk Paper Limited (jkpaper) Q2 FY26: Consolidated Turnover Up 11%, PAT Rises 36%
-
Industrials2 days agoAmara Raja Energy & Mobility Limited (are&m) Q2 FY27: Revenue Up 13%
-
Auto Parts2 days agoJay Bharat Maruti Limited Q2 FY’27 Results: PAT Up 72.59%, Revenue Grows 41.97%
-
Consumer Cyclical2 days agoSheela Foam Limited Q2 & H1 FY27 Results: Revenue Surpasses ₹1,000 Cr, PAT Up 6.6x Yoy